Product candidate
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Milestones
Solid tumors circAde
circVec
circRNA vector
circRNA vector
Infectious disease,
circVac
Rare disease
ONCOS-102
mRNA vector1
mRNA vector1
PD-1 Resistant Melanoma
Re-challenge combination w/aPD-1 & CTLA-4
Mutant KRAS1
Pancreatic cancer & Multiple Myeloma
TG01/QS-21 +/- anti-PD-1
Cancer Indication:
Solid tumors circAde
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication:
Infectious disease, circVac
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication:
Rare disease
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
Target screening and selection
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
Target screening and selection
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication: PD-1 Resistant Melanoma
Combination with: Re-challenge combination w/aPD-1 & CTLA-4
Product candidate: ONCOS-102 mRNA vector1
Next expected event: TBD 2023-24
Initiation of phase 2 trial (USA)
Combination with: Re-challenge combination w/aPD-1 & CTLA-4
Product candidate: ONCOS-102 mRNA vector1
Next expected event: TBD 2023-24
Initiation of phase 2 trial (USA)
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication:
Pancreatic cancer & Multiple Myeloma
Combination with: TG01/QS-21 +/- anti-PD-1
Product candidate: Mutant KRAS1
Next expected event: 1H 2023
First patient dosed (USA & EU)
Combination with: TG01/QS-21 +/- anti-PD-1
Product candidate: Mutant KRAS1
Next expected event: 1H 2023
First patient dosed (USA & EU)
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Two trials run and financed by collaboration partners
1Pending additional financing or partnership